Highlights

  • Several ASX-listed companies that have gained more than 200% over the past year released significant operational and strategic updates on 14 May 2026.
  • Mining and resource-focused companies continued to dominate market attention, particularly around project development and Acquisition activity.
  • Healthcare diagnostics company Lumos Diagnostics also attracted investor attention following another milestone payment tied to its US-funded paediatric study.

A group of ASX-listed companies that have generated extraordinary share price gains over the past 12 months returned to investor focus on Thursday after releasing new operational and strategic updates to the market.

The announcements spanned gold and silver development, copper exploration, and healthcare diagnostics, reflecting continued investor appetite for companies capable of delivering transformational growth stories despite broader market Volatility.

Among the standout performers were Kingsgate Consolidated Ltd (ASX:KCN), Locksley Resources Ltd (ASX:LKY) and Lumos Diagnostics Holdings Ltd (ASX:LDX), each of which has delivered share price gains exceeding 200% over the past year.

Kingsgate Consolidated Extends Strategic Push in Chile

Kingsgate Consolidated Ltd remained one of the strongest-performing resource stocks on the ASX over the past year, with shares rising approximately 238% despite a modest decline during Thursday’s session.

The company announced a major acquisition tied to its Nueva Esperanza Silver-Gold Project in Chile, securing Royalty and water rights that management said would materially improve the project’s long-term Economics and development flexibility.

The transaction removes several financial obligations that had previously weighed on the project, including annual pre-production royalty commitments and net smelter royalties tied to future production. Kingsgate also secured long-term water rights in Chile’s Atacama region, an increasingly strategic asset given water Scarcity and strict permitting conditions in the region.

Management framed the acquisition as a significant de-risking milestone for Nueva Esperanza, particularly as the company advances technical workstreams and explores development Options for the silver-gold project.

Importantly, the company also disclosed that it is evaluating strategic value realisation pathways, including the possibility of a separate ASX listing for Nueva Esperanza. That aspect of the announcement appeared to attract particular market interest given the improving silver price environment and growing investor focus on standalone precious metals development stories.

Kingsgate said the transaction would be funded through existing cash reserves, with the company reporting approximately A$139 million in group cash as at the end of April 2026.

The latest announcement reinforces how investors have increasingly rewarded companies capable of simplifying project structures and improving development economics amid stronger Commodity market conditions.

Locksley Resources Expands Copper-Gold Footprint

Locksley Resources Ltd also remained firmly on investor radars after the company announced an option agreement to acquire the Iron Duke Copper & Gold Project in New South Wales.

The stock has surged roughly 367% over the past year, reflecting growing investor interest in junior exploration companies exposed to copper and critical minerals themes.

The newly announced Iron Duke acquisition complements Locksley’s existing Tottenham Project within the Cobar region and strengthens the company’s district-scale exploration strategy.

The project hosts historical high-grade copper and gold mineralisation, with prior drilling returning multiple significant intercepts across a mineralised system extending roughly 550 metres along strike. Historical resource estimates cited by the company outlined inferred resources of 1.3 million tonnes grading 1.0% copper and 0.6 grams per tonne gold.

Investors appeared particularly encouraged by the project’s near-term exploration potential, with several drill-ready targets already identified and additional prospects remaining largely untested.

The acquisition structure may also have supported market confidence. Locksley secured the option through a relatively modest upfront payment combined with milestone-based consideration tied to future resource growth and project advancement. This structure potentially limits immediate financial strain while preserving exposure to exploration upside.

The company said it intends to commence a 2,000-metre drilling program during the option period while validating historical data and progressing toward updated JORC-compliant resource estimates.

The announcement comes amid sustained investor interest in copper-focused exploration companies as long-term electrification and infrastructure themes continue supporting Demand expectations for the metal.

Lumos Diagnostics Advances US Expansion Strategy

Outside the mining sector, Lumos Diagnostics Holdings Ltd attracted attention after announcing another milestone payment linked to its BARDA-funded paediatric clinical study for FebriDx.

Although Lumos shares fell more than 7% during Thursday trading, the stock remains up approximately 333% over the past year, making it one of the ASX’s strongest-performing healthcare names over that period.

The company confirmed it had completed milestone seven in its paediatric study program after enrolling 250 patients, triggering a further US$670,000 payment from the Biomedical Advanced Research and Development Authority (BARDA).

That brings total milestone payments received under the agreement to US$2.59 million so far, with total committed non-dilutive funding reaching approximately US$6.2 million if all future milestones are successfully completed.

The paediatric study is designed to support expanded US regulatory clearance for FebriDx, allowing the diagnostic tool to be used in younger children aged between two and twelve years.

Lumos has already secured FDA 510(k) clearance and CLIA Waiver status for FebriDx use in patients aged 12 to 64 years earlier this year, significantly expanding the product’s addressable market across US healthcare settings.

Management said the ongoing study progression supports the company’s strategy to broaden FebriDx adoption across acute respiratory infection diagnostics while potentially reducing unnecessary antibiotic prescriptions.

The company’s strong share price performance over the past year has reflected growing investor optimism surrounding regulatory progress, expanding commercial opportunities, and increasing adoption potential in the US diagnostics market.

Conclusion

The strong one-year share price gains recorded by Kingsgate Consolidated, Locksley Resources and Lumos Diagnostics underscore how operational delivery and strategic positioning continue driving investor interest across the ASX small-cap market. Today’s announcements reinforced those themes, with each company advancing important initiatives tied to project development, exploration expansion, or commercial progress. While market volatility remains a Factor across global equities, investors continue closely monitoring companies capable of delivering meaningful catalysts that may reshape Long-term Growth trajectories.